ERBB2 and breast cancer: In recent years, a novel immunotherapeutic tool, namely, chitosan nanobubbles carrying a DNA vaccine and equipped with anti-CD11C surface antibodies for targeting dendritic cell recognition, has been developed for the treatment of HER2-positive breast cancer [40].